Strategies for caring for the well cancer survivor

,; ,; ,

Applied Evidence

Strategies for caring for the well cancer survivor

J Fam Pract. 2018 October;67(10):624-628,630-635

PDF Download

References

1. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2016-2017. Atlanta, GA: American Cancer Society; 2016. www.cancer.org/research/cancer-facts-statistics/survivor-facts-figures.html. Accessed July 25, 2018.

2. Survivorship. NCCN Guidelines (version 1.2017). Fort Washington, PA: National Comprehensive Cancer Network; 2017. www.nccn.org/professionals/physician_gls/default.aspx#supportive. Accessed July 26, 2018.

3. Kendall C, Decker KM, Groome PA, et al. Use of physician services during the survivorship phase: a multi-province study of women diagnosed with breast cancer. Curr Oncolog. 2017;24:81-89.

4. Snyder CF, Earle CC, Herbert RJ, et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008;26:1073-1079.

5. Hewitt M, Greenfield S, Stovall E (eds); Institute of Medicine and National Research Council. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington DC: The National Academies Press; 2006. www.nap.edu/read/11468/chapter/1. Accessed July 25, 2018.

6. Survivorship care plan. New York, NY: Memorial Sloan Kettering Cancer Center. www.mskcc.org/hcp-education-training/survivorship/survivorship-care-plan. Accessed August 11, 2018.

7. Fuentes AC, Lambird JE, George TJ, et al. Cancer survivor’s history and physical. South Med J. 2017;110:37-44. http://sma.org/southern-medical-journal/article/cancer-survivors-history-physical/. Accessed July 26, 2018.

8. Salz T, Oeffinger KC, McCabe MS, et al. Survivorship care plans in research and practice. CA Cancer J Clin. 2012;62:101-117.

9. Birken SA, Mayer DK, Weiner BJ. Survivorship care plans: prevalence and barriers to use. J Cancer Educ. 2013;28:290-296.

10. American College of Surgeons Commission on Cancer. Cancer program standards 2012: Ensuring patient-centered care. V1.2.1. www.facs.org/~/media/files/quality%20programs/cancer/coc/programstandards2012.ashx. Accessed July 25, 2018.

11. NCCN guidelines for treatment of cancer by site. NCCN Guidelines (version 1.2018). Fort Washington, PA: National Comprehensive Cancer Network; 2018. www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed July 25, 2018.

12. Spronka I, Korevaar JC, Burgers JS, et al. Review of guidance on recurrence risk management for general practitioners in breast cancer, colorectal cancer and melanoma guidelines. Family Pract. 2017;34:154-160.

13. Merkow RP, Korenstein D, Yeahia R, et al. Quality of cancer surveillance clinical practice guidelines: specificity and consistency of recommendations. JAMA Intern Med. 2017;177:701-709.

14. Muradali D, Kennedy EB, Eisen A, et al. Breast screening for survivors of breast cancer: a systematic review. Prev Med. 2017;103:70-75.

15. Giannarini G, Kessler TM, Thoeny HC, et al. Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol. 2010;58:486-494.

16. Sisler JJ, Seo B, Katz A, et al. Concordance with ASCO guidelines for surveillance after colorectal cancer treatment: a population-based analysis. J Oncol Pract. 2012;8:e69-e79.

17. Ehdaie B. Atoria CL, Lowrance WT, et al. Adherence to surveillance guidelines after radical cystectomy: a population-based analysis. Urol Oncol. 2014;32:779-784.

18. Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97:1354-1365.

19. Donin N, Filson C, Drakaki A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer. 2016;122:3075-3086.

20. Holder AE, Ramirez AG, Gallion K. Depressive symptoms in Latina breast cancer survivors: a barrier to cancer screening. Health Psycholog. 2014;33:242-248.

21. Dyer G, Larsen SR, Gilroy N, et al. Adherence to cancer screening guidelines in Australian survivors of allogenic blood and marrow transplantation (BMT). Cancer Med. 2016;5:1702-1716.

22. Mandelzweig L, Chetrit A, Amitai T, et al. Primary prevention and screening practices among long-term breast cancer survivors. Cancer Causes Control. 2017;28:657-666.

23. Bishop MM, Lee SJ, Beaumont JL, et al. The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls. Biol Blood Marrow Transplant. 2010;16:207-214.

24. Uhlig A, Mei J, Baik I, et al. Screening utilization among cancer survivors: a meta-analysis. J Public Health (Oxf). 2018;40:129-137.

25. Hilal T, Rudy DW. Radiation-induced breast cancer: the question of early breast cancer screening in Hodgkin’s lymphoma survivors. Oxf Med Case Reports. 2016;2016:17-18.

26. Lin K, Croswell JM, Koenig H, et al. Prostate-specific antigen-based screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force [Internet]. Evidence Syntheses No. 90. AHRQ Publication No. 12-05160-EF-1. Rockville, MD: Agency for Healthcare Research and Quality (US); October 2011. www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032900/. Accessed July 25, 2018.

27. US Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;320:674-686.

28. Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12 Suppl 1:4-10.

29. Jung JY, Lee JM, Kim MS, et al. Comparison of fatigue, depression, and anxiety as factors affecting posttreatment health-related quality of life in lung cancer survivors. Psychooncology. 2018;27:465-470.

30. Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatment. Nat Rev Clin Oncol. 2014;11:597-609.

31. Medysky ME, Temesi J, Culos-Reed SN, et al. Exercise, sleep and cancer-related fatigue: are they related? Neurophysiol Clin. 2017;47:111-122.

32. Oh HS, Sea WS. Systematic review and meta-analysis of the correlates of cancer-related fatigue. Worldviews Evid Based Nurs. 2011;8:191-201.

33. Qu D, Zhang Z, Yu X, et al. Psychotropic drugs for the management of cancer-related fatigue: a systematic review and meta-analysis. Eur J Cancer Care (Engl). 2016;25:970-979.

34. Escalante CP, Manzullo EF. Cancer-related fatigue: the approach and treatment. J Gen Intern Med. 2009;24(suppl 2):S412-S416.

35. Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 2017;3:961-968.

36. Glare PA, Davies PS, Finlay E, et al. Pain in cancer survivors. J Clin Oncol. 2014;32:1739-1747.

37. Davies PS. Chronic pain management in the cancer survivor: tips for primary care providers. Nurse Pract. 2013;39:28-38.

38. Boland EG, Ahmedzai SH. Persistent pain in cancer survivors. Curr Opin Support Palliat Care. 2017;11:181-190.

39. Sears CS, Robinson JW, Walker LM. A comprehensive review of sexual health concerns after cancer treatment and the biopsychosocial treatment options available to female patients. Eur J Cancer Care (Engl). 2017;27:e12738.

40. Schou Bredal I, Smeby NA, Ottesen S, et al. Chronic pain in breast cancer survivors: comparison of psychological, surgical, and medical characteristics between survivors with and without pain. J Pain Symptom Manage. 2014;48:852-862.

41. Sutradhar R, Lokku A, Barbera L. Cancer survivorship and opioid prescribing rates: a population-based matched cohort study among individuals with and without a history of cancer. Cancer. 2017;123:4286-4293.

42. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep. 2016;65:1-49.

43. Davis MP, Mehta Z. Opioids and chronic pain: where is the balance? Curr Oncol Rep. 2016;18:71.

44. Von Ah D. Cognitive changes associated with cancer and cancer treatment: state of the science. Clin J Oncol Nurs. 2015;19:47-56.

45. Moore HC. An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain’. Oncology (Williston Park). 2014;28:797-804.

46. Asher A. Cognitive dysfunction among cancer survivors. Am J Phys Med Rehabil. 2011;90(suppl):S16-S26.

47. Joly F, Rigal O, Noal S, et al. Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology. 2011;20:1251-1258.

48. Attention, thinking or memory problems. American Society of Clinical Oncology Cancer.Net. April 2018. www.cancer.net/navigating-cancer-care/side-effects/attention-thinking-or-memory-problems. Accessed July 25, 2018.

49. Kucherer S, Ferguson RJ. Cognitive behavioral therapy for cancer-related cognitive dysfunction. Curr Opin Support Palliat Care. 2017;11:46-51.

50. Derry HM, Jaremka LM, Bennet JM, et al. Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial. Psychooncology. 2015;24:958-966.

51. Treanor CJ, McMenamin UC, O’Neill RF, et al. Non-pharmacological interventions for cognitive impairment due to systemic cancer treatment. Cochrane Database Syst Rev. 2016 Aug 16;(8):CD011325.

52. Mitchell AJ, Ferguson DW, Gill J, et al. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2013;14:721-732.

53. Inhestern L, Beierlein V, Bultmann JC, et al. Anxiety and depression in working-age cancer survivors: a register-based study. BMC Cancer. 2017;17:347.

54. Partridge AH, Jacobsen PB, Andersen BL. Challenges to standardizing the care for adult cancer survivors: highlighting ASCO’s fatigue and anxiety and depression guidelines. Am Soc Clin Oncol Educ Book. 2015:188-194.

55. Andersen BL, Yang HC, Farrar WB, et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer. 2008;113:3450-3458.

56. Yi JC, Syrjala KL. Anxiety and depression in cancer survivors. Med Clin N Am. 2017;101:1099-1113.

57. Zhu G, Zhang X, Wang Y, et al. Effects of exercise intervention in breast cancer survivors: a meta-analysis of 33 randomized controlled trials. Onco Targets Ther. 2016;9:2153-2168.

58. Hawkins NA, Soman A, Lunsford N, et al. Use of medications for treating anxiety and depression in cancer survivors in the United States. J Clin Oncol. 2017;35:78-85.

59. Ostuzzi G, Matcham F, Dauchy S, et al. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2015 June 1;(6):CD011006.

60. Laoutidis ZG, Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013;13:140.

61. Lydiatt WM, Bessette D, Schmid KK, et al. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol Head Neck Surg. 2013;139:678-686.

62. Lavigne JE, Heckler C, Mathews JL, et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat. 2012;136:479-486.

63. Okwuosa TM, Anzevino S, Rao R. Cardiovascular disease in cancer survivors. Postgrad Med J. 2017;93:82-90.

64. Plana, JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911-939.

65. Lancellotti, P, Nkomo VT, Badano LP, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr. 2013;26:1013-1032.

Yet adherence to cancer surveillance recommendations is poor. A study of patients with colon cancer demonstrated that only 12% met all recommended surveillance guidelines.¹⁶ A study of patients with bladder cancer after radical cystectomy showed that only 9% met recommended surveillance more than 2 years after diagnosis.¹⁷ Those dismal statistics may be the result of provider oversight—not patient reluctance.

In the colon cancer study, for example, compliance with follow-up colonoscopy was 80% but compliance with carcinoembryonic antigen testing was only 22%.¹⁶ In the bladder cancer study, follow-up urine cytology was obtained in only 23% of patients, although 75% completed recommended imaging.¹⁷

Although surveillance remains the oncologist’s responsibility, visits to the FP provide an opportunity to review surveillance and order needed laboratory testing and other studies, including imaging.

3. Screen for new cancers

The risk of a second cancer is elevated for cancer survivors compared with the risk of a primary cancer in the healthy general population; some survivors have a lifetime risk of a second cancer as high as 36%.¹⁸ Risk varies by cancer type (TABLE 3¹⁹). Some of this variation is due to the impact of smoking: Smoking-related cancers have the highest risk of second malignancy.¹⁹ Genetic predisposition to malignant transformation is also theorized to contribute to increased risk. Second malignancies are dangerous; 55% of patients die of the second cancer compared with only 13% of their initial cancer.¹⁹

A study of colorectal cancer survivors showed that primary care visits increased in each of the 5 years after diagnosis, during which time oncology visits decreased steadily.

Studies show that cancer survivors display varying adherence with recommended screening for second cancers. In a study of Latina cancer survivors, depressive symptoms were associated with lower screening compliance.²⁰ A study of survivors of hematologic cancer showed a low rate of cancer screening and high fear of cancer recurrence—suggesting avoidance due to fear.²¹ Other studies, however, show similar or increased compliance with screening in cancer survivors.^22,23A meta-analysis of 19 studies determined that, overall, cancer survivors receive 25% to 38% more recommended screening than the general population.²⁴

Continue to: Few guidelines exist to guide FPs...